Related Experiment Video
Updated: Feb 21, 2026

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
Published on: June 6, 2025
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study
Peter J Dodd1, Charalambos Sismanidis2, James A Seddon3
1School of Health and Related Research, University of Sheffield, Sheffield, UK.
Insights
Drug-resistant tuberculosis in children is significantly underestimated, with millions infected and thousands developing disease annually. This highlights a critical gap in diagnosis and treatment, impacting global public health strategies for pediatric tuberculosis.
Area of Science:
- Pediatric infectious diseases
- Global epidemiology
- Antimicrobial resistance
Background:
- Children infected with Mycobacterium tuberculosis face a high risk of developing tuberculosis disease, which is difficult to diagnose.
- Existing estimates suggest a substantial underreporting of isoniazid-resistant and multidrug-resistant (MDR) tuberculosis cases in children.
- The burden of drug-resistant tuberculosis infection and disease, including various resistance types and uncertainties, remains unquantified in pediatric populations.
Purpose of the Study:
- To estimate the global burden of drug-resistant tuberculosis infection and disease in children.
- To quantify the prevalence of specific drug resistance patterns, including isoniazid monoresistance, MDR, and extensively drug-resistant (XDR) tuberculosis.
- To provide country-level, regional, and global data on drug-resistant tuberculosis in pediatric populations.
Main Methods:
- A mathematical model of tuberculosis in children was integrated with drug-resistance pattern analysis.
- Data from the WHO Global Project on Antituberculosis Drug Resistance Surveillance (1988-2014) were utilized.
- Bayesian approaches and sampling methods were employed to estimate infection prevalence, disease incidence, and proportions of drug resistance.
Main Results:
- An estimated 850,000 children developed tuberculosis in 2014, with significant proportions having isoniazid-monoresistant, MDR, and XDR forms.
- Approximately 67 million children were estimated to be infected with Mycobacterium tuberculosis, including millions with drug-resistant strains.
- Regions like Africa and Southeast Asia bear the highest numbers, while the Eastern Mediterranean, European, and Western Pacific regions show high proportions of drug resistance.
Conclusions:
- The actual occurrence of drug-resistant tuberculosis in children far exceeds diagnosed cases, indicating a large reservoir of drug-resistant infection.
- These findings have significant implications for empirical treatment and preventive therapy strategies in affected regions.
- There is an urgent need to improve surveillance and diagnostic capabilities for drug-resistant tuberculosis in children worldwide.
Background:
After infection with Mycobacterium tuberculosis, children are at an increased risk of progression to tuberculosis disease; a condition that can be challenging to diagnose. New estimation approaches for children have highlighted the gap between incidence and notifications of M tuberculosis, and suggest there are more cases of isoniazid-resistant and multidrug-resistant (MDR) disease than are identified. No work has yet quantified the burden of drug-resistant infection, or accounted for other types of drug resistance or sampling uncertainty.
Methods:
We combined a mathematical model of tuberculosis in children with an analysis of drug-resistance patterns to produce country-level, regional, and global estimates of drug-resistant infection and disease. We determined drug resistance using data from the Global Project on Antituberculosis Drug Resistance Surveillance at WHO, from surveys and surveillance reported between 1988 and 2014. We combined 1000 sampled proportions for each country from a Bayesian approach with 10 000 sampled country estimates of tuberculosis disease incidence and M tuberculosis infection prevalence. We estimated the proportions of tuberculosis cases at a country level with isoniazid monoresistance, rifampicin monoresistance, multidrug resistance (MDR), fluoroquinolone-resistant multidrug resistance, second-line injectable-resistant multidrug resistance, and extensive multidrug resistance with resistance to both a fluoroquinolone and a second-line injectable (XDR).
Findings:
We estimated that 850 000 children developed tuberculosis in 2014; 58 000 with isoniazid-monoresistant tuberculosis, 25 000 with MDR tuberculosis, and 1200 with XDR tuberculosis. We estimate 67 million children are infected with M tuberculosis; 5 million with isoniazid monoresistance, 2 million with MDR, and 100 000 with XDR. Africa and southeast Asia have the highest numbers of children with tuberculosis, but the WHO Eastern Mediterranean region, European region, and Western Pacific region also contribute substantially to the burden of drug-resistant tuberculosis because of their much higher proportions of resistance.
Interpretation:
Far more drug-resistant tuberculosis occurs in children than is diagnosed, and there is a large pool of drug-resistant infection. This finding has implications for approaches to empirical treatment and preventive therapy in some regions of the world.
Funding:
UNITAID.
Related Concept Videos
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...

